VEGFB - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ADRB2	adrenoceptor beta 2	Adrenoceptors G alpha (s) signalling events Ub-specific processing proteases Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Spermine Amphetamine Betaxolol Bethanidine Isoetharine Cabergoline Metoprolol Metoprolol Olanzapine Atenolol Norepinephrine Timolol Phenylpropanolamine Dipivefrin Sotalol Carteolol Nortriptyline Propranolol Labetalol Bisoprolol Epinephrine Paroxetine Trimipramine Cryptenamine Orciprenaline Dobutamine Pseudoephedrine Alprenolol Ritodrine Ritodrine Terbutaline Bitolterol Phenoxybenzamine Salmeterol Pindolol Formoterol Salbutamol Ergoloid mesylate Isoprenaline Arbutamine Amiodarone Carvedilol Desipramine Propafenone Acebutolol Nadolol Levobunolol Metipranolol Aripiprazole Arformoterol Fenoterol Pirbuterol Bevantolol Penbutolol Ephedra sinica root Ephedrine Mephentermine Procaterol Clenbuterol Bambuterol Oxprenolol Putrescine Spermidine Celiprolol Nebivolol Indacaterol Bedoradrine NCX 950 Asenapine Droxidopa Bufuralol Protokylol (S)-carazolol Bopindolol Bupranolol Befunolol Olodaterol Vilanterol Viloxazine Arotinolol Doxofylline Racepinephrine Dihydroergocornine DL-Methylephedrine Etafedrine Tulobuterol Levosalbutamol Dihydroergocristine Methoxyphenamine	Asthma
Novel	FLT1	fms related receptor tyrosine kinase 1	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib
Novel	FOSL1	FOS like 1, AP-1 transcription factor subunit	NGF-stimulated transcription NGF-stimulated transcription
Novel	KLHL12	kelch like family member 12	Degradation of DVL
Novel	NRP1	neuropilin 1	Neurophilin interactions with VEGF and VEGFR Signaling by ROBO receptors Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling Signal transduction by L1 CHL1 interactions Attachment and Entry
Novel	SF1	splicing factor 1	mRNA Splicing - Major Pathway	Artenimol
Novel	TFB1M	transcription factor B1, mitochondrial	Transcriptional activation of mitochondrial biogenesis rRNA modification in the mitochondrion
Novel	TNXB	tenascin XB	ECM proteoglycans		Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel	UCP2	uncoupling protein 2	The fatty acid cycling model
Novel	UCP3	uncoupling protein 3	The fatty acid cycling model
Novel	VEGFA	vascular endothelial growth factor A	Platelet degranulation Regulation of gene expression by Hypoxia-inducible Factor Signaling by VEGF VEGF ligand-receptor interactions VEGF binds to VEGFR leading to receptor dimerization Interleukin-4 and Interleukin-13 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	Bevacizumab Minocycline Gliclazide Carvedilol Ranibizumab Pidolic acid Pegaptanib Vandetanib ABT-510 Veglin Denibulin SNS-032 Bevasiranib Dalteparin Aflibercept Chondroitin sulfate Foreskin keratinocyte (neonatal) Vanucizumab Brolucizumab Faricimab	Gastric cancer
	ADRB2	adrenoceptor beta 2	Adrenoceptors G alpha (s) signalling events Ub-specific processing proteases Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Spermine Amphetamine Betaxolol Bethanidine Isoetharine Cabergoline Metoprolol Metoprolol Olanzapine Atenolol Norepinephrine Timolol Phenylpropanolamine Dipivefrin Sotalol Carteolol Nortriptyline Propranolol Labetalol Bisoprolol Epinephrine Paroxetine Trimipramine Cryptenamine Orciprenaline Dobutamine Pseudoephedrine Alprenolol Ritodrine Ritodrine Terbutaline Bitolterol Phenoxybenzamine Salmeterol Pindolol Formoterol Salbutamol Ergoloid mesylate Isoprenaline Arbutamine Amiodarone Carvedilol Desipramine Propafenone Acebutolol Nadolol Levobunolol Metipranolol Aripiprazole Arformoterol Fenoterol Pirbuterol Bevantolol Penbutolol Ephedra sinica root Ephedrine Mephentermine Procaterol Clenbuterol Bambuterol Oxprenolol Putrescine Spermidine Celiprolol Nebivolol Indacaterol Bedoradrine NCX 950 Asenapine Droxidopa Bufuralol Protokylol (S)-carazolol Bopindolol Bupranolol Befunolol Olodaterol Vilanterol Viloxazine Arotinolol Doxofylline Racepinephrine Dihydroergocornine DL-Methylephedrine Etafedrine Tulobuterol Levosalbutamol Dihydroergocristine Methoxyphenamine	Asthma
	FLT1	fms related receptor tyrosine kinase 1	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib
	FOSL1	FOS like 1, AP-1 transcription factor subunit	NGF-stimulated transcription NGF-stimulated transcription
	KLHL12	kelch like family member 12	Degradation of DVL
	NRP1	neuropilin 1	Neurophilin interactions with VEGF and VEGFR Signaling by ROBO receptors Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling Signal transduction by L1 CHL1 interactions Attachment and Entry
	SF1	splicing factor 1	mRNA Splicing - Major Pathway	Artenimol
	TFB1M	transcription factor B1, mitochondrial	Transcriptional activation of mitochondrial biogenesis rRNA modification in the mitochondrion
	TNXB	tenascin XB	ECM proteoglycans		Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
	UCP2	uncoupling protein 2	The fatty acid cycling model

Search Results for: VEGFB